Coronavirus (COVID-19) - Latest Information for Patients and Visitors

(La más reciente información para pacientes y visitantes)

 

Read Now (Lea ahora)
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF)

view all Clinical Trials

Overview

Acute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks. AE account for about 1/2 the deaths in IPF patients, and are refractory to all medical therapies attempted to date.

Considerable preliminary data shows pathological B-cell abnormalities and autoantibodies are present in AE-IPF and associated with disease severity.

The experimental therapy here (therapeutic plasma exchange plus rituximab plus intravenous immunoglobulin) is mechanistically targeted to ameliorate autoantibody-mediated pulmonary injury. Anecdotal pilot studies indicate these treatments have significant benefit for a disease syndrome that has, until now, been almost invariably inexorable. This clinical trial has the potential to profoundly affect current paradigms and treatment approaches to patients with AE-IPF.

Contact

For more information about this trial or to inquire about eligibility, email breathe@tuhs.temple.edu or call 215-707-1359.